Patents by Inventor Harpreet Singh
Harpreet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12036271Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 10, 2022Date of Patent: July 16, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 12039301Abstract: A method for developing a containerized application using a pipeline platform consisting of a plurality of stages with associated development tools, the method comprising the steps of: receiving application parameters and a check-in code for the containerized application; generating a configuration file based on the application parameters, the configuration file containing configuration content including insert code; embedding the insert code into the check-in code; dynamically provisioning an opinionated pipeline based on contents of the configuration file, the opinionated pipeline including the plurality of stages with the associated development tools; setting up one or more control gates in one or more of the plurality of stages; receiving customized code for the containerized application, the customized code representing modifications of the insert code; and packaging the containerized application to include code contents of the check-in code, the customized code, and the insert code; wherein the containeType: GrantFiled: July 29, 2022Date of Patent: July 16, 2024Assignee: Royal Bank of CanadaInventors: Ian Kerins, Benny Derick Marianayagam, Parth Sondarva, Sahil Bhardwaj, Yasamin Ahmadzadeh, Navpreet Kaur, Michael David Webster, Biren H Parmar, Juan Carlos Chang Zheng, Jong Ming Char, Chi Kit Yim, Harpreet Singh
-
Patent number: 12029785Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 18, 2022Date of Patent: July 9, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Publication number: 20240222128Abstract: Embodiments herein are generally directed to electronic device manufacturing and, more particularly, to systems and methods for forming substantially void-free and seam-free tungsten features in a semiconductor device manufacturing scheme. In one embodiment, a substrate processing system features a processing chamber and a gas delivery system fluidly coupled to the processing chamber. The gas delivery system includes a first radical generator for use in a differential inhibition treatment process and a second radical generator for use in a chamber clean process. The processing system is configured to periodically condition the first radial generator by forming a plasma of a relatively low amount of a halogen-based gas.Type: ApplicationFiled: May 6, 2021Publication date: July 4, 2024Inventors: Mingrui ZHAO, Peiqi WANG, Kai WU, Harpreet SINGH, Michael C. KUTNEY
-
Patent number: 12023372Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 18, 2022Date of Patent: July 2, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Publication number: 20240209500Abstract: Embodiments herein are generally directed to electronic device manufacturing and, more particularly, to systems and methods for forming substantially void-free and seam-free tungsten features in a semiconductor device manufacturing scheme. In one embodiment, a substrate processing system features a processing chamber and a gas delivery system fluidly coupled to the processing chamber. The gas delivery system includes a first radical generator for use in a differential inhibition treatment process and a second radical generator for use in a chamber clean process.Type: ApplicationFiled: May 6, 2021Publication date: June 27, 2024Inventors: Xi CEN, Wei Min CHAN, Kai WU, Peiqi WANG, Mingrui ZHAO, Michael C. KUTNEY, Kazuya DAITO, Harpreet SINGH
-
Patent number: 12018064Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 6, 2021Date of Patent: June 25, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
-
Publication number: 20240193590Abstract: A method of facilitating the dispensing of destination currency from a destination ATM to a user traveling to a destination country comprising the system provider establishes a currency exchange system which comprises at least two system accounts established for the system provider and funded by the users residing in the respective country with deposits of home currency in at least one financial institution in a respective country. The system provider provides each of the users virtual tokens equal in value to the amount of home currency deposited to the system account of the home country. The user requests a virtual debit card with an amount of destination currency, and the system provider debits the virtual tokens in equal value. The user requests an amount of destination currency from a destination ATM, and the system provider debits the destination currency from the system account in the destination country.Type: ApplicationFiled: February 26, 2024Publication date: June 13, 2024Inventor: Harpreet Singh
-
Patent number: 12006349Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 6, 2021Date of Patent: June 11, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
-
Patent number: 12005105Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: November 4, 2021Date of Patent: June 11, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Colette Song
-
Publication number: 20240180598Abstract: A fixation device for providing rotation stability to a femoral neck fracture. The device includes a bone plate having at least one opening, a compression screw housing extendable through the opening of the bone plate, a compression screw being at least partially disposed within the bore of the housing and selectively moveable through the bore, and a collapsible and expandable anchoring member coupled to the compression screw. The anchoring member is configured to transition between a collapsed condition and an expanded condition upon advancement of the anchoring member from the compression screw housing to rotationally stabilize the compression screw within a femur.Type: ApplicationFiled: February 13, 2024Publication date: June 6, 2024Inventors: Jetinder Singh, Venkateswaran Perumal, Harpreet Singh, Diksha Babhoota, Abhishek Kulkarni
-
Publication number: 20240182522Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: ApplicationFiled: January 5, 2024Publication date: June 6, 2024Inventors: Toni WEINSCHENK, Steffen WALTER, Jens FRITSCHE, Colette SONG, Harpreet SINGH
-
Patent number: 11999774Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: May 7, 2021Date of Patent: June 4, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 11986497Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: February 9, 2023Date of Patent: May 21, 2024Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Patent number: 11975058Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 11, 2022Date of Patent: May 7, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 11975042Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: July 23, 2021Date of Patent: May 7, 2024Assignee: Immatics Biotechnologies GmbHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 11970444Abstract: Disclosed herein is an efficacious process for preparation of highly purified Glycopyrrolate tosylate in high yield. The process is being cost effective, environment friendly and easily scalable to high volume industrial production.Type: GrantFiled: November 6, 2019Date of Patent: April 30, 2024Assignee: HARMAN FINOCHEM LIMITEDInventors: Vijay Trimbak Kadam, Dhananjay Uddhavrao Ed Aki, Ravindra Bhausaheb Pagire, Mayur Sanjay Kulkarni, Harpreet Singh Minhas, Gurpreet Singh Minhas
-
Patent number: 11969455Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: June 25, 2021Date of Patent: April 30, 2024Assignee: Immatics Biotechnologies GmbHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 11965013Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.Type: GrantFiled: October 29, 2021Date of Patent: April 23, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
-
Publication number: 20240127522Abstract: Examples are disclosed that relate to generating expressive avatars using multi-modal three-dimensional face modeling and tracking. One example includes a computer system comprising a processor coupled to a storage system that stores instructions. Upon execution by the processor, the instructions cause the processor to receive initialization data describing an initial state of a facial model. The instructions further cause the processor to receive a plurality of multi-modal data signals. The instructions further cause the processor to perform a fitting process using the initialization data and the plurality of multi-modal data signals. The instructions further cause the processor to determine a set of parameters based on the fitting process, wherein the determined set of parameters describes an updated state of the facial model.Type: ApplicationFiled: December 6, 2022Publication date: April 18, 2024Applicant: Microsoft Technology Licensing, LLCInventors: Harpreet Singh SAWHNEY, Benjamin Eliot LUNDELL, Anshul Bhavesh SHAH, Calin CRISTIAN, Charles Thomas HEWITT, Tadas BALTRUSAITIS, Mladen RADOJEVIC, Kosta GRUJCIC, Ivan STOJILJKOVIC, Paul Malcolm MCILROY, John Ishola OLAFENWA, Jouya JADIDIAN, Kenneth Mitchell JAKUBZAK